Dr. Christopher Rogers, founder of San Diego Orthobiologics Medical Group (SDOMG) and medical director for Personalized Stem Cells, Inc. (PSC), is pleased to announce that they have obtained FDA approval to treat patients with severe COVID-19 using stem cells.

In record time, Personalized Stem Cells, Inc. has received approval from the U.S. Food and Drug Administration to conduct a clinical trial of stem cells for the treatment of patients with severe COVID-19 (1).  Stem cell therapy has already shown encouraging results in studies conducted in Spain, Israel, and China.  Dr. Rogers and his coauthors recently published a landmark peer-reviewed scientific article on the rationale behind the use of stem cells to treat COVID-19 (2).  Support from entire team at SDOMG and PSC was critical to achieving this exciting accomplishment.  We are eager to initiate this clinical trial and demonstrate the safety and efficacy of this innovative and promising therapy.


1)  WFMJ: Personalized Stem Cells Receives FDA Approval to Treat COVID-19 Patients

2)  Journal of Translational Medicine: Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

3)  Personalized Stem Cells Announces Completion of Enrollment for FDA Approved Stem Cell Clinical Trial for Knee Arthritis


Pin It on Pinterest

Share This